Amira achieves two clinical development milestones in FLAP system for asthma Amira Pharmaceuticals, Inc. Announced today that its FLAP system, which can be partnered with GlaxoSmithKline, provides achieved two scientific development milestones liquid jelly . These milestones are related to the successful progression of the program to Phase 2 studies, which explore the use of the Amira found out FLAP inhibitor in sufferers suffering from asthma.
We are pleased that Amorfix has identified the unique features and great things about our RabMAb platform for developing top quality and high affinity antibodies with the potential to recognize unique epitopes. We look forward to assisting Amorfix in building its product pipeline .. Amorfix, Epitomics collaborate to develop high-affinity monoclonal antibodies against cancers targets Amorfix Life Sciences and Epitomics, Inc. Announced today that they have entered into an contract to develop high-affinity monoclonal antibodies against a number of targets for tumor. Amorfix has identified many disease specific epitopes on misfolded proteins with their proprietary ProMIS computational platform discovery technology, which is used by Epitomics to generate highly particular monoclonal antibodies . Epitomics, with its partners together, has effectively generated over a dozen humanized therapeutic antibody drug leads targeting immune illnesses and cancers using RabMAb technology and its proprietary Mutation Lineage Guided humanization technology.